If you travel outside the US, you may have experienced the Direct-to-Consumer pharmacy model. In Guatemala, for example, you don’t need a prescription. You just head to the pharmacy and purchase what you need from the pharmacist. This direct route cuts out the physician fee and insurance bill, but all costs are out-of-pocket.
In the US, there is a growing movement to develop direct-to-consumer (DTC) platforms. You still need a prescription, but your insurance company is out of the mix. Some pharmaceutical companies have started offering DTC platforms like LillyDirect, Pfizer’s initiatives, and Bristol Myers Squibb’s Eliquis 360. These programs are being promoted as innovative ways to cut costs by bypassing middlemen and selling directly to patients.
It’s easy to see the appeal of this model – the drug company is offering wholesale prices to consumers like Sam’s Club. The issue is that our healthcare system is so complicated that there are always unintended consequences to broad stroke solutions. In the case of DTC, patients could be giving up valuable cost-sharing opportunities with their health plan and other members.
DTC Platform Pros
Let’s talk about how DTC could really benefit patients and change the game:
- Transparency and simplicity. Patients can see a clear, upfront price for a medication without navigating complex formularies or hidden costs.
- Access for the uninsured or underinsured. For people paying entirely out-of-pocket, DTC discounts (e.g., 40–50% off list price) can be lower than retail pharmacy prices.
- Convenience. Many DTC platforms are paired with telehealth and home delivery, making it easier and faster for patients to obtain prescriptions.
- Niche value where insurance falls short. Some patients with commercial insurance still lack coverage for certain high-demand drugs, like GLP-1s for weight management. In those cases, DTC provides an alternative route to access the medication.
DTC Platform Cons
The biggest limitation is that the above listed pros apply to two small subsets of patients, those without insurance coverage and those wealthier patients who can afford to pay hundreds of dollars out-of-pocket every month.
- Drugs are still expensive. Even with discounts, drugs like Zepbound ($499/month) or Eliquis ($346/month) are still far more expensive than what insured patients typically pay (around $38 for Eliquis).
- Not integrated with insurance. DTC purchases don’t apply toward deductibles or maximums, limiting their real value.
- Fragmentation. By bypassing traditional coverage channels, DTC adds complexity to an already fragmented system and raises questions about prescribing practices linked to telehealth partnerships.
How RazorMetrics Addresses Affordability Within Insurance
Unlike DTC platforms, RazorMetrics is built to lower costs inside the health insurance system where most Americans access their prescriptions.
- Physician-directed: Our platform engages prescribers directly to recommend safe, clinically sound alternatives like generics, biosimilars, and therapeutic equivalents.
- Integrated savings: Because switches occur within the insured benefit design, members pay less at the counter and those costs count toward deductibles and out-of-pocket maximums.
- Savings for all stakeholders: Members save on copays, employers save on total pharmacy spend, and physicians retain control of prescribing decisions.
- Proven at scale: RazorMetrics clients have achieved tens of millions in savings without disrupting care.
Our Take
DTC platforms may offer convenience and incremental discounts, but they are not a systemic solution to America’s drug affordability crisis. Real savings happen when affordability is addressed within the insurance system, not outside it.
RazorMetrics delivers that solution: physician-directed, clinically sound, and integrated into the coverage structures that matter most to members and plan sponsors.
